The stock of Aimmune Therapeutics Incorporated (NASDAQ:AIMT) registered a decrease of 0.13% in short interest. AIMT’s total short interest was 2.47M shares in September as published by FINRA. Its down 0.13% from 2.48 million shares, reported previously. With 237,100 shares average volume, it will take short sellers 10 days to cover their AIMT’s short positions. The short interest to Aimmune Therapeutics Incorporated’s float is 10.56%. About 68,288 shares traded hands. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 8.73% since February 8, 2016 and is uptrending. It has underperformed by 7.76% the S&P500.
Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The company has a market cap of $672.82 million. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy , is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It currently has negative earnings. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.